Overview

PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.

Status:
Recruiting
Trial end date:
2022-10-12
Target enrollment:
Participant gender:
Summary
A Phase 1 Open-label, Two-cohort, One-sequence Crossover Study to Investigate the Effect of P glycoprotein Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics, Safety, and Tolerability of Sitravatinib in Healthy Subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Mirati Therapeutics Inc.
Treatments:
Itraconazole
Rifampin